Alvotech Reports Update on Initial AVT02 Biologics License Application
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
Cancer
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children...
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) --...
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not...
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA...
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance...
Fate Therapeutics to Participate at Upcoming September Investor Conferences
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Bagsværd, Denmark and Watertown, Mass, US, 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today...
Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on...
MiNK Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and...
AVEO Oncology Announces Participation at Investor Conferences in September
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering...
X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia
Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&ABOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE)...
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapySALT LAKE...
Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma
NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...
Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development...
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Press release Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage...
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4/5-adapted bivalent...
Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting
Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of...
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Lab Reaching Out to Georgia-based School Administrators to Assist with Outbreak PlansNEW YORK, NY and TEL AVIV, Israel, Aug. 26,...